BR112012018132A2 - "marcadores de células - tronco tumorais e uso dos mesmos". - Google Patents

"marcadores de células - tronco tumorais e uso dos mesmos".

Info

Publication number
BR112012018132A2
BR112012018132A2 BR112012018132A BR112012018132A BR112012018132A2 BR 112012018132 A2 BR112012018132 A2 BR 112012018132A2 BR 112012018132 A BR112012018132 A BR 112012018132A BR 112012018132 A BR112012018132 A BR 112012018132A BR 112012018132 A2 BR112012018132 A2 BR 112012018132A2
Authority
BR
Brazil
Prior art keywords
tumor stem
stem cell
cell markers
tumor
stem cells
Prior art date
Application number
BR112012018132A
Other languages
English (en)
Portuguese (pt)
Inventor
Goletz Steffen
Karsten Uwe
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of BR112012018132A2 publication Critical patent/BR112012018132A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112012018132A 2010-01-20 2011-01-20 "marcadores de células - tronco tumorais e uso dos mesmos". BR112012018132A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29673810P 2010-01-20 2010-01-20
EP10000527A EP2347769A1 (en) 2010-01-20 2010-01-20 Cancer stem cell markers and uses thereof
PCT/EP2011/000217 WO2011089004A1 (en) 2010-01-20 2011-01-20 Cancer stem cell markers and uses thereof

Publications (1)

Publication Number Publication Date
BR112012018132A2 true BR112012018132A2 (pt) 2017-06-20

Family

ID=42173400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018132A BR112012018132A2 (pt) 2010-01-20 2011-01-20 "marcadores de células - tronco tumorais e uso dos mesmos".

Country Status (8)

Country Link
US (1) US20120294859A1 (enExample)
EP (2) EP2347769A1 (enExample)
JP (2) JP2013517487A (enExample)
CN (1) CN102753199A (enExample)
AU (1) AU2011208874B2 (enExample)
BR (1) BR112012018132A2 (enExample)
CA (1) CA2786212A1 (enExample)
WO (1) WO2011089004A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
CN106434561A (zh) 2010-09-03 2017-02-22 艾伯维施特姆森特克斯有限责任公司 细胞亚群的鉴定和富集
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
US9341619B2 (en) 2013-03-14 2016-05-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hyposialylation disorders
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
SG11201510740YA (en) 2013-09-17 2016-01-28 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
EP3797793A1 (en) 2014-04-18 2021-03-31 The Research Foundation of the State University of New York at Buffalo Humanized anti-tf-antigen antibodies
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
CN103969437B (zh) * 2014-04-22 2017-03-22 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3904388A1 (en) 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same
EP3154582A4 (en) 2014-05-28 2018-01-10 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CN107430127B (zh) * 2015-01-24 2020-08-28 中央研究院 癌症标记及其使用方法
CA2979640A1 (en) 2015-02-25 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sialylation-increasing therapies for diseases associated with oxidative stress
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
KR20180114210A (ko) 2016-03-08 2018-10-17 아카데미아 시니카 N-글리칸의 모듈 합성 방법 및 그의 어레이
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20190134994A (ko) * 2017-03-29 2019-12-05 글리코토페 게엠베하 Muc1 및 cd3에 결합하는 다중특이적 항체 작제물
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110161241A (zh) * 2019-04-30 2019-08-23 丁晓昆 一种快速检测生物组织切片cosmc基因突变试剂盒
TWI873265B (zh) 2020-01-03 2025-02-21 美商英塞特公司 抗ｃｄ７３抗體及其用途
PH12022551621A1 (en) 2020-01-03 2023-10-23 Incyte Corp Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CN113388024A (zh) * 2020-03-18 2021-09-14 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
KR20230030626A (ko) * 2020-06-30 2023-03-06 글리코토페 게엠베하 루이스 y에 대한 인간화된 항체
KR20230157940A (ko) 2020-12-29 2023-11-17 인사이트 코포레이션 A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
JP2024504406A (ja) * 2021-01-25 2024-01-31 ユニオジェン・オサケユフティオ 膀胱がんのバイオマーカーとしてのＦＵＣα（１－２）Ｇａｌ糖鎖構造の使用
AU2022331944A1 (en) * 2021-07-16 2024-02-01 Université de Montréal Novel tumor-specific antigens for cancer stem cells and uses thereof
CN113804531B (zh) * 2021-09-10 2024-02-06 北京大学 一种细胞高活性染色方法
CN115960169A (zh) * 2021-10-09 2023-04-14 清华大学深圳国际研究生院 特异性靶向非小细胞肺癌肿瘤干细胞的多肽及其应用
CN119955728A (zh) * 2022-08-01 2025-05-09 首都医科大学附属北京胸科医院 恶性表型大细胞肺癌细胞株及其应用
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法
CN121319187B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种与cd176蛋白结合的羊驼源纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
WO2007079448A2 (en) * 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
US20110190166A1 (en) * 2006-05-26 2011-08-04 Susan Wong Erythroid progenitor cells and methods for producing parvovirus b19 therein

Also Published As

Publication number Publication date
EP2525832A1 (en) 2012-11-28
AU2011208874A1 (en) 2012-08-02
US20120294859A1 (en) 2012-11-22
CN102753199A (zh) 2012-10-24
WO2011089004A1 (en) 2011-07-28
JP2013517487A (ja) 2013-05-16
EP2347769A1 (en) 2011-07-27
CA2786212A1 (en) 2011-07-28
JP2016047848A (ja) 2016-04-07
AU2011208874B2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
AR092818A1 (es) Anticuerpo tau humanizado
BR112014026703A2 (pt) inibidores de dna-pk
BRPI0821145B8 (pt) uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
BR112012021296A2 (pt) imunoconjugados e anticorpos de receptor de folato 1 e usos dos mesmos.
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos
UY35147A (es) Anticuerpos anti-ceacam5 y usos de éstos.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
GT201100011DA (es) Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
UA113712C2 (xx) Антитіло до fap і способи його застосування
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), C07K 16/30 (2006.01), C07K 1

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13/11/2018.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI